Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactococcus lactis expressing Stat-CPSC5
- Development stage
- Preclinical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
*Lactococcus lactis* expressing Stat-CPSC5 is a bioengineered live biotherapeutic product (probiotic) designed for the precision targeting and elimination of *Fusobacterium nucleatum*, a bacterial pathogen strongly associated with the development and progression of colorectal cancer (CRC). The therapy utilizes a strain of *Lactococcus lactis* (typically MG1363) engineered to secrete a guided antimicrobial peptide (gAMP) known as Stat-CPSC5. This gAMP construct consists of a Statherin-derived guide peptide (Stat) that specifically binds to the FomA porin on the outer membrane of *F. nucleatum*, linked to a synthetic antimicrobial peptide (CPSC5). By delivering the antimicrobial payload directly to the surface of the target pathogen, the probiotic achieves selective depletion of *F. nucleatum* while preserving the diversity and richness of the surrounding gut microbiota. This targeted approach aims to mitigate the pro-tumorigenic and pro-inflammatory environment promoted by *F. nucleatum* in the colon, potentially serving as a therapeutic or preventive strategy for CRC.
- Other names
- Stat-CPSC5-expressing Lactococcus lactisStat-CPSC-5-expressing Lactococcus lactisStat-CPSC 5-expressing Lactococcus lactisLactococcus lactis MG1363 expressing Stat-CPSC5gAMP-expressing probiotic
02
Targets
FomA (Fusobacterium nucleatum porin FomA)
Beyond the preview
Go deeper on Lactococcus lactis expressing Stat-CPSC5.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactococcus lactis expressing Stat-CPSC5.